Clinical Determinants of Disease Progression in Patients With Limb Girdle Muscular Distrophy Type 2E

Completed

• Conditions: LGMD2E
• Interventions: Other: Exon 3 truncating mutation; Other: Any other mutation in SGBC gene

• Registration Number: NCT04509609
• Lead Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Brief Summary

A retrospective observational study that will enable us to collect retrospective data from the clinical records of LGMD 2E patients in order to highlight any possible correlation between:

* clinical variables and patient age,

* clinical variables and other clinical variables,

* clinical variables and clinical outcomes. The study will help to define the natural history of this rare disease and to ameliorate the management of these patients.

Detailed Description

Retrospective observational study. Retrospective data from clinical charts of patients affected by LGMD 2E will be collected after the subscription of informed consent.Data considered will include any clinical variable measured, both objective and subjective. All data obtained will be anonimized before any treatment. Data will be grouped according to the age of the patient, in order to have more data for each age and to gain a trustable description of the disease progression. The possible correlation of each variable to age, to other variables and to objective clinical outcomes will be studied. Clinical outcomes considered will include age of loss of deambulation, age of introduction of respiratory assist, age of introduction of cardiological therapy. Data collected will also be divided in two groups according to different genetic diagnosis in order to evaluate phenotipical differences of genotypical clesses. First group will count all patient with the truncating mutation c.377_384duplCAGTAGGA in exon 3, both in heterozigosis and in homozigosis Second group will include all the other patients.

Both on the global data collection and on data divided according to genotype, statistical analysis will be performed. Those analysis will study linear regression both with the univariate, bivariate and multivariate model.

Study Timeline

• Study Start: 2020-06-01
• Study First Submitted: 2020-07-09
• Study First Submitted QC: 2020-08-10
• Study First Posted: 2020-08-12
• Primary Completion: 2020-09-30
• Study Completion: 2021-09-30
• Status Verified: 2022-03
• Last Update Submitted: 2022-03-29
• Last Update Posted: 2022-03-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 33

Inclusion Criteria

• Gene based diagnosis of LGMD 2E
• Subscription of informed consent when applicable

Exclusion Criteria

• Lacking gene based diagnosis of LGMD 2E
• Lacking subscription of informed consent when applicable

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
LGMD 2E with a genetic diagnosis	Exon 3 truncating mutation	Any patient affected by LGMD 2E with a genetic diagnosis
LGMD 2E with a genetic diagnosis	Any other mutation in SGBC gene	Any patient affected by LGMD 2E with a genetic diagnosis

Primary Outcome Measures

Name	Time	Method
Natural history	december 2020	The clinical progression of the disease will be studied considering for each clinical variable its evolution according to patients' ages. This both in overall cohort and in genetic subgroups.

Secondary Outcome Measures

Name	Time	Method
Guidelines	december 2020	The collection of clinical variables describing the progression of the disease will enable a better clinical management of these patients

Trial Locations

Locations (1)

IRCCS Ca' Granda Ospedale Maggiore Policlinico; 🇮🇹 Milano, Italy